These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 20382619

  • 1. A promising new inotrope: levosimendan.
    Fotbolcu H, Duman D.
    Anadolu Kardiyol Derg; 2010 Apr; 10(2):176-82. PubMed ID: 20382619
    [Abstract] [Full Text] [Related]

  • 2. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C, Tousoulis D, Koumallos N, Marinou K, Stefanadis C.
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [Abstract] [Full Text] [Related]

  • 3. Levosimendan in the treatment of cardiogenic shock.
    Buerkem B, Lemm H, Krohe K, Dietz S, Raaz U, Buerke U, Russ M, Schlitt A, Werdan K.
    Minerva Cardioangiol; 2010 Aug; 58(4):519-30. PubMed ID: 20938415
    [Abstract] [Full Text] [Related]

  • 4. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F.
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [Abstract] [Full Text] [Related]

  • 5. Levosimendan: dual mechanisms for acute heart failure...and beyond?
    Ng TM, Akhter MW.
    Minerva Cardioangiol; 2005 Dec; 53(6):565-84. PubMed ID: 16333239
    [Abstract] [Full Text] [Related]

  • 6. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL, Fitzpatrick JT.
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [Abstract] [Full Text] [Related]

  • 7. Levosimendan: current status and future prospects.
    Archan S, Toller W.
    Curr Opin Anaesthesiol; 2008 Feb; 21(1):78-84. PubMed ID: 18195615
    [Abstract] [Full Text] [Related]

  • 8. Pharmacologic treatment of heart failure due to ventricular dysfunction by myocardial stunning: potential role of levosimendan.
    García González MJ, Domínguez Rodríguez A.
    Am J Cardiovasc Drugs; 2006 Feb; 6(2):69-75. PubMed ID: 16555860
    [Abstract] [Full Text] [Related]

  • 9. The utility of levosimendan in the treatment of heart failure.
    Lehtonen L, Põder P.
    Ann Med; 2007 Feb; 39(1):2-17. PubMed ID: 17364447
    [Abstract] [Full Text] [Related]

  • 10. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.
    Pathak A, Lebrin M, Vaccaro A, Senard JM, Despas F.
    J Clin Pharm Ther; 2013 Oct; 38(5):341-9. PubMed ID: 23594161
    [Abstract] [Full Text] [Related]

  • 11. Levosimendan: implications for clinicians.
    McBride BF, White CM.
    J Clin Pharmacol; 2003 Oct; 43(10):1071-81. PubMed ID: 14517189
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Levosimendan: a new option in acute cardiac failure.
    Holley AD, Ziegenfuss M.
    Emerg Med Australas; 2006 Oct; 18(5-6):505-9. PubMed ID: 17083641
    [No Abstract] [Full Text] [Related]

  • 18. Evidence-based use of levosimendan in different clinical settings.
    De Luca L, Colucci WS, Nieminen MS, Massie BM, Gheorghiade M.
    Eur Heart J; 2006 Aug; 27(16):1908-20. PubMed ID: 16682381
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.